[5] We theorized that by using low doses of a statin (rosuvastatin) every other day (EOD), a significant LDL-C reduction may still be achieved while also avoiding the dose-dependent adverse effects. A number of other drugs (eg, bile acid resins, ezetimibe, niacin) are available to reduce LDL-C in patients who are statin intolerant; however, these agents are less effective compared with statin therapy. 2008;42(3):341-346. [7,8,9,10] Additionally, moderate-to-high statin doses possess a rather flat dose response relative to low doses. Please use this form to submit your questions or comments on how to make this article more useful to clinicians. You've successfully added to your alerts. [21] Atorvastatin also has a long half-life (~14 h) and has demonstrated effectiveness with EOD dosing. fIncludes 0-1 risk factors. Asian people may be particularly sensitive to Crestor and require lower dosages. [1] Nonspecific muscle complaints or joint pain without elevated creatine kinase levels have been reported in approximately 5% of clinical trial participants;[2] however, the range is wide (0.3-33%). cIncludes CHD or CHD risk equivalent, 10-y risk >20%. Dosing a statin (rosuvastatin) every other day (EOD) may provide significant lipoprotein changes while avoiding common adverse effects in this statin-intolerant population. Commenting is limited to medical professionals. ATP = Adult Treatment Panel; CHD = coronary heart disease; LDL-C = low-density lipoprotein cholesterol. Take CRESTOR, by mouth, one time each day. eIndicates optional goal from ATP-III Update. Ischemic Stroke May Hint at Underlying Cancer, Topol: US Betrays Healthcare Workers in Coronavirus Disaster, The 6 Dietary Tips Patients Need to Hear From Their Clinicians, Type of previous statin intolerance, n (%), Previous number of intolerable statins, n (%), Previous intolerances to individual statins, n. This website also contains material copyrighted by 3rd parties. Recently, a significant 39% reduction in LDL-C was achieved with rosuvastatin (10 mg) EOD among patients without a previous statin intolerance. gThree patients had experienced intolerance more than once; therefore, intolerance totals are >100%. [6] These factors produce the common clinical challenge of achieving an aggressive LDL-C goal in a high-risk patient intolerant to statin therapy. Show abstract. Possible explanations include the positive psychological effect of EOD treatment or lower plasma and muscle concentrations. cIncludes CHD or CHD risk equivalent, 10-y risk >20%. Dosing a statin (rosuvastatin) every other day (EOD) may provide significant lipoprotein changes while avoiding common adverse effects in this statin-intolerant population. 2008;42(3):341-346. eIncludes ≥2 risk factors, 10-y CHD risk <10%. The Annals of Pharmacotherapy. 2008;42(3):341-346. If you log out, you will be required to enter your username and password the next time you visit. We cannot specify why the EOD regimen was better tolerated by these patients. You must declare any conflicts of interest related to your comments and responses. Burnout Might Really Be Depression; How Do Doctors Cope? an = 44. bIndicates a family history of premature CHD (CHD in male first-degree relative <55 y of age; CHD in female first-degree relative <65 y of age). Endocrinological Features of Hartsfield Syndrome in an Adult Patient With a Novel Mutation of FGFR1, The Effect of Sprint Interval Training on Body Composition of Postmenopausal Women, Hypothalamic–Pituitary and Growth Disorders in Survivors of Childhood Cancer, Advances in Allergen Immunotherapy for Asthma, Remote, Non-Physician-Led Care Cuts LDL, BP in High-Risk Patients, Statins Beneficial in Elderly, Guidelines Should Be Strengthened, AACE Issues 'Cookbook' Algorithm to Manage Dyslipidemia, First-of-Its Kind Guideline on Lipid Monitoring in Endocrine Diseases, Women With Heterozygous FH Less Likely to Receive Treatment, Amazon Launches Online Pharmacy in New Contest With Drug Retail, Pharmacotherapy Considerations in Hospitalized Patients With COVID-19 Pneumonia. However, 4 patients in our study who had previously received rosuvastatin therapy daily and reported an adverse effect were able to tolerate the EOD regimen, thus making this explanation unlikely for all of the patients. Overall, these agents have a remarkable safety profile, although some patients are intolerant of them. Endocrinological Features of Hartsfield Syndrome in an Adult Patient With a Novel Mutation of FGFR1, The Effect of Sprint Interval Training on Body Composition of Postmenopausal Women, Hypothalamic–Pituitary and Growth Disorders in Survivors of Childhood Cancer, Advances in Allergen Immunotherapy for Asthma, Remote, Non-Physician-Led Care Cuts LDL, BP in High-Risk Patients, Statins Beneficial in Elderly, Guidelines Should Be Strengthened, AACE Issues 'Cookbook' Algorithm to Manage Dyslipidemia, First-of-Its Kind Guideline on Lipid Monitoring in Endocrine Diseases, Women With Heterozygous FH Less Likely to Receive Treatment, Amazon Launches Online Pharmacy in New Contest With Drug Retail, Pharmacotherapy Considerations in Hospitalized Patients With COVID-19 Pneumonia. Methods: We performed a retrospective analysis of patients treated with EOD rosuvastatin at 2 lipid specialty clinics: the University of Kansas Lipid, Atherosclerosis, and LDL-Apheresis Center and the Hartford Hospital Cholesterol Management Center. Our findings are similar to previous data from case reports and small trials. [16] The study reported here examined the effect and tolerance of EOD rosuvastatin therapy in a considerably larger cohort. Hydroxymethylglutaryl coenzyme A reductase inhibitors (statins) are well established as treatment for lowering low-density lipoprotein cholesterol (LDL-C) and reducing cardiovascular events. James M Backes, PharmD,1,2 Carmelo V Venero, MD,3 Cheryl A Gibson, PhD,4 Janelle F Ruisinger, PharmD,5 Patricia A Howard, PharmD FCCP BCPS,5 Paul D Thompson, MD,6,7 Patrick M Moriarty, MD 8 1Department of Pharmacy Practice, Schools of Pharmacy and Medicine, University of Kansas, Kansas City, KS 2Lipid, Atherosclerosis, Metabolic and LDL-Apheresis Center, University of Kansas Medical Center, Kansas City, KS 3Hartford Hospital, Hartford, CT 4Department of Internal Medicine, University of Kansas Medical Center, Kansas City, KS 5Department of Pharmacy Practice, Schools of Pharmacy and Medicine, University of Kansas, Kansas City, KS 6The Henry Low Heart Center, Hartford Hospital, Hartford, CT 7University of Connecticut, Farmington, CT 8Department of Internal Medicine; Lipid, Atherosclerosis, Metabolic and LDL-Apheresis Center, University of Kansas Medical Center, Kansas City, KS. 3 Every-other-day dosing, especially of the newer statins with longer half-lives (ie, rosuvastatin and atorvastatin), has also been shown to preserve lipid-lowering benefits.